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Abstract
Only in recent years have phospholipase A2 enzymes (PLA2s) emerged as cancer targets. In this work, we report the first
detection of elevated PLA2 activities in plasma from patients with colorectal, lung, pancreatic, and bladder cancers as
compared to healthy controls. Independent sets of clinical plasma samples were obtained from two different sites. The first
set was from patients with colorectal cancer (CRC; n = 38) and healthy controls (n = 77). The second set was from patients
with lung (n = 95), bladder (n = 31), or pancreatic cancers (n = 38), and healthy controls (n = 79). PLA2 activities were analyzed
by a validated quantitative fluorescent assay method and subtype PLA2 activities were defined in the presence of selective
inhibitors. The natural PLA2 activity, as well as each subtype of PLA2 activity was elevated in each cancer group as compared
to healthy controls. PLA2 activities were increased in late stage vs. early stage cases in CRC. PLA2 activities were not
influenced by sex, smoking, alcohol consumption, or body-mass index (BMI). Samples from the two independent sites
confirmed the results. Plasma PLA2 activities had approximately 70% specificity and sensitivity to detect cancer. The marker
and targeting values of PLA2 activity have been suggested.
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Introduction
Cancer is one of the major health burdens worldwide. More
than 1.6 million new cancer cases and over 577,000 deaths from
cancer are projected to occur in the United States in 2012 [1].
Lung cancer (LC) and colorectal cancer (CRC) are among the
most frequent types of cancers. Pancreatic and bladder cancers
count for (3–7% of all cancers), but pancreatic cancer (PC) is one
of the deadest cancers, with a dismal 5-year survival rate of 6%
[1]. The success of current cancer treatments depends strongly on
the time of diagnosis, with early detection and identification of
high risk patient populations resulting in the most favorable overall
survivals in these diseases [1,2]. It is expected that early detection
and screening of high risk patient populations may have the most
significant impact on altering overall survival in these diseases.
Thus, there is an urgent need for efficient and sensitive early
detection methods [3]. While imaging-based detection methods,
including spiral computerized axial tomography (CT) and
colonoscopy are effective early detection methods for LC and
CRC, respectively [4], they are rather expensive and inconvenient.
In addition, modern imaging techniques have a high incidence of
discovery of lung nodules, many of which are falsely positive, but
still calling for additional and sometimes painful examinations [5].
Molecular approaches to cancer diagnosis through biomarkers
measured by non-invasive means could significantly improve the
specificity and sensitivity of cancer detection [5]. In particular,
serologic biomarkers may be the most useful in early detection due
to the minimal invasiveness, cost-effectiveness, and convenience.
Moreover, serological biomarkers identifying novel cancer-related
genes and/or molecules may provide new insight into the biology
of cancers and may also become attractive targets for treatment
[3].
Phospholipase A2 enzymes (PLA2s) are the major enzymes
producing the cyclooxygenase-2 (COX-2) substrate, arachidonic
acid (AA), as well as lysophospholipids. Both of these classes of
products are signaling molecules involved in cancers. However,
only in recent years have PLA2s emerged as cancer targets [6].
More than 30 enzymes that possess PLA2 or related activity have
been identified in mammals [7]. They are divided into four groups
based on their cellular localization, substrate specificity, and
calcium-dependence [8], including cytosolic (cPLA2), calcium-
independent (iPLA2), secreted (sPLA2), and lipoprotein-associated
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PLA2 (Lp-PLA2). In cancer, most of the attention has been focused
on sPLA2 and cPLA2 [8]. We and others have shown that iPLA2 is
functionally involved in promoting the development of ovarian
cancer (OC) and other cancers, in vitro and in vivo [9–13]. sPLA2
and Lp-PLA2 are secreted enzymes. In contrast, both cPLA2 and
iPLA2 are cytosolic enzymes and their extracellular existence has
only been shown to be related to exosomes from RBL-2H3 cells (a
mast and basophil cell line) [14]. Exosomes are 40–100 nm
diameter membrane vesicles released from multivesicular bodies
by intact cells and are known to participate in intercellular
signaling [15]. We have recently detected extracellular- and
exosome-free iPLA2 and cPLA2 activities in ascites and tissues
from OC patients [16].
In the current work we have focused on PLA2 activities rather
than expression of individual PLA2 enzymes and examined PLA2
activities in blood plasma samples from patients with different
cancers, in comparison with those from healthy controls. We used
our recently validated quantitative, convenient, highly reproduc-
ible PLA2 assay method [16] and showed for the first time that
plasma PLA2 activities from patients with CRC, LC, PC, and
bladder cancer (BC) were significantly higher than those of healthy
controls. In addition, PLA2 activities were correlated with tumor
stages in CRC. Other potential influential factors, including sex,
age, smoking and alcohol consumption were also examined in this
study.
Materials and Methods
Human sample collection and processing
Two sets of independently collected clinical plasma samples
were obtained for this study. The first set from the Indiana
University School of Medicine (IUSM) focused on CRC patients
and healthy controls screened by colonoscopy and found negative
for adenomatous polyps and CRC. Blood samples collected in the
presence of EDTA were centrifuged at 1,750 g for 15 min at 15–
24uC, aliquoted in siliconized Eppendorf tubes and stored at
280uC. The second set of samples was from patients with lung,
bladder, or pancreatic cancers, as well as healthy controls. These
samples were collected by the Hoosier Oncology Group (HOG) in
Indianapolis, IN as part of the study entitled, ‘‘A Biological Sample
Collection Protocol of Patients with and without Metastatic Solid
Organ Malignancies: Hoosier Oncology Group Study BANK09-
138’’. Blood samples were centrifuged at 3,500 rpm for 30 min.
The aliquoted samples were stored at 270uC. HOG is a non-
profit medical research organization. Although it is a separate
entity, IUSM is a supporting organization for board appointments
and IRB approvals for HOG. Three separate IRB protocols for
collecting and/or use the blood samples related to this work have
been approved by the same IUSM Institutional Review Board
(Protocol numbers: 0670-81, 0808-24, 0905-20). Written informed
consent forms were obtained from all subjects and all clinical
investigation had been conducted according to the principles
expressed in the Declaration of Helsinki.
Reagents and inhibitors
The PLA2 substrate 1-O-(6-Dabcyl-Aminohexanoyl)-2-O-(6-
(12-BODIPY-Dodecanoyl) Aminohexanoyl)-sn-3-Glyceryl Phos-
phatidylcholine (DBPC) was from Echelon Bioscience (Salt Lake
City, UT, USA). Bromoenol lactone (BEL) and methyl arachido-
nylfluorophosphonate (MAFP) were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA).
PLA2 enzymatic activity analyses
PLA2 activities were analyzed using the fluorescent substrate
DBPC, a fluorogenic phosphatidylcholine substrate [17]. Plasma
samples (0.1 mL) were mixed with DBPC (0.2 mg in PBS) to final
volume 200 mL. The fluorescence was read at intervals over
several hours on a Victor3V plate reader (Perkin Elmer, Waltham,
MA, USA). PLA2 activities were expressed as change in
fluorescence intensity/min/mL of plasma. As previously described
[16], we selected conditions to distinguish PLA2 activity derived
from different subtypes: a) the ‘‘natural’’ PLA2 activity without any
exogenous additives, b) the iPLA2 activity in the presence of 5 mM
EDTA (a divalent cation chelator to block all PLA2s requiring
calcium, including sPLA2 and cPLA2), c) the sPLA2 activity in the
presence of 1.2 mM calcium chloride (the natural ionized calcium
concentration in blood [18]) and MAFP (10 mM, a dual inhibitor
of cPLA2 and iPLA2), and d) the cPLA2 activity in the presence of
100 mM calcium chloride and bromoenol lactone (BEL, 10 mM, a
selective inhibitor for iPLA2).
Table 1. Demographic data for participants from IUSM and HOG study.
Age (years) Sex (%) Race (%)
No. Mean SD P value Male Female P value White
African
American Others P value
Participants from IUSM
Healthy 77 51.6 13.5 40.3 59.7 89.6 9.1 1.3
CRC 38 56.0 13.4 0.1075 44.7 55.3 0.6470 86.8 5.3 7.9 0.4501
Participants from HOG
Healthy 79 42.7 12.0 77.2 22.8 89.3 2.7 8.0
LC 95 63.2 9.5 ,0.0001 64.2 35.8 0.0621 89.5 8.4 2.1 0.0654
BC 31 70.5 10.0 ,0.0001 87.1 12.9 0.2438 93.6 6.5 0.0 0.1868
PC 38 68.7 8.7 ,0.0001 63.2 36.8 0.1102 92.1 5.3 2.6 0.4327
CRC: colorectal cancer; LC: Lung cancer; BC: Bladder cancer; PC: Pancreatic cancer; SD, standard deviation; HOG: Hoosier Oncology Group.
In the HOG set: N For gender, the overall P value is 0.0339. N For Age, the overall P value is ,0.0001. N For race, the overall P value is 0.2352. Since it was not
significant, it was not recommended to perform pair-wise comparisons. Nonetheless, P values for pair-wise comparisons are given to be consistent with the other two
variables. All pair-wise comparisons are against healthy controls.
doi:10.1371/journal.pone.0057081.t001
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Statistical Analysis
Categorical variables were summarized as counts with percent-
ages and continuous variables were summarized as means with
standard deviations (SD) across the healthy control, and cancer
groups. The Chi-square test was used to test the associations
between disease statuses and categorical covariates such as sex,
race, smoking, and alcohol drinking. For continuous covariates
such as age and BMI, one-way ANOVA was used to test the
overall difference and Student t-test was used to test the pair-wise
difference across disease statuses. Linear regression was used to
assess the univariate association between PLA2 measurements and
Figure 1. Plasma PLA2 activities were elevated in cancer groups vs. healthy controls. Comparison of PLA2 activities in the healthy control
(normal colonoscopy; n = 77) and CRC (n = 38) groups. A. Comparison of PLA2 activities in the healthy (n = 79) and other cancer groups. Lung cancer
(LC, n = 95), bladder cancer (BC, n = 31) and pancreatic cancer (PC, n = 38). The distribution of the natural and individual groups of PLA2 activities were
analyzed as described in Materials and Methods. The mean values of PLA2 activities were presented by the ‘‘+’’ in the figure. *P,0.05; **P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0057081.g001
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covariates. Logistic regression was used to evaluate the classifica-
tion performance of PLA2 measurements. Bootstrap was used to
internally validate the classification performance using 1000
samples [19]. Each sample had the same size as the original data
set and was used to develop the model. The results were then
tested in the original data. Areas under the curve (AUCs) were
calculated for each repeat. All tests were two-sided. Given the
exploratory nature of this study, no adjustments for multiple
comparisons were adopted. P values ,0.05 were considered to be
statistically significant. All analyses were performed using SAS
software Version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Subject demographic data
The demographic data for the study participants are summa-
rized in Table 1. For the IUSM CRC set samples, 41.7% of the
overall participants were male, 88.7% were white, and the mean
age was 53.1 years. The age, sex, and race composition were not
significantly different in control vs. CRC groups (P values .0.05;
Table 1). For the second set of samples, the age in the healthy
control group was significantly younger than each of the three
cancer groups (Table 1). Although males were dominant in each
group, they were not significantly different from the second set of
healthy controls. 71.2% of the overall participants were male,
90.4% were white, and the mean age was 58.3 years (Table 1).
Reproducibility and stability of the PLA2 assays
We have recently validated the quantitative nature of the
DBPC-based PLA2 assays and optimized the conditions for
biological fluids and tissues samples [16]. When each of 8
representative plasma samples were analyzed three times, the
PLA2 activity values reproducible, with an average standard
deviation (SD) 13.5 (1.3%). We also tested the PLA2 activity
stability by comparing them in samples before storage to those in
the same samples stored at 280uC for one month, as well as the
effect of freeze-and-thaw on the PLA2 activities in 8 representative
samples. As previously reported [16], PLA2 activities were stable
with SDs ,35.8 (5.8%). In addition, we showed that in the
presence of all other assay components including inhibitor(s) used
in this study, but in the absence of blood or other biological
samples, the non-specific hydrolysis of the DBPC substrate was
negative and negligible (data not shown).
The natural PLA2, cPLA2, iPLA2, and sPLA2 activities were
elevated in cancer samples vs. healthy controls
Blood iPLA2 and cPLA2 activities have not been previously
reported in human samples. We analyzed the natural PLA2
(defined as the PLA2 activities measured under the conditions
without any modifiers, which may be lower than the sum of the
subgroup PLA2 activities measured under modified conditions), as
well as cPLA2, iPLA2, and sPLA2 activities in plasma samples.
Except for the healthy vs. CRC cPLA2 activity, all other
comparisons showed that PLA2 activities were significantly
elevated in the cancer groups (Fig. 1A and 1B). PLA2 activity
values across plasma samples from LC, BC, and PC patients were
not significantly different (P values .0.05).
Since sPLA2 is secreted, it was expected that sPLA2 activity
would account for the major portion of the PLA2 activity detected
in the blood. However, in our results, high levels of iPLA2 and
cPLA2 and low levels of sPLA2 activities were observed in all
plasma samples. Blood exosomes may be the carriers of these
activities [15]. We used differential centrifugation steps as we
described recently [16] to determine whether these activities could
Figure 2. PLA2 activities were higher in late stage CRC samples.
The natural and individual groups of PLA2 activities were progressively
increased by tumor stage. Stage I and II (n = 7), Stage III and IV (n = 31).
*Student t-test, P,0.05.
doi:10.1371/journal.pone.0057081.g002
Table 2. Clinical characteristics and PLA2 activities in the CRC cases.
PLA2 iPLA2 cPLA2 sPLA2
No. Mean SD P value Mean SD P value Mean SD P value Mean SD P value
Primary site 0.6856* 0.7407* 0.6419* 0.3410*
Colon 24 1412.3 473.75 1302.8 428.78 1424.0 480.16 476.3 199.33
Rectum 14 1348.0 460.33 1254.7 428.33 1347.7 489.95 408.3 195.50
Previous treatment 0.6543** 0.3081** 0.3348** 0.6212**
Surgery only 7 1340.3 382.29 1193.1 286.55 1303.4 424.30 435.5 92.75
CT and RT 3 1614.8 542.80 1599.5 626.64 1755.4 707.50 495.9 219.34
Surgery and CT 10 1496.8 596.54 1399.5 543.97 1521.1 633.55 519.8 264.44
Surgery, CT and RT 5 1459.0 437.46 1402.9 322.07 1511.8 322.27 472.8 200.95
Untreated 13 1252.2 404.71 1128.6 341.99 1221.8 327.50 388.5 183.68
*Student t-test.
**One-way ANOVA.
CT: chemotherapy; RT: radiotherapy.
doi:10.1371/journal.pone.0057081.t002
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be associated with platelets, exosomes, or other microvesicles. Two
blood samples were first centrifuged at 1,750 g for 15 min to
remove most blood cells and the supernatant was termed S1. S1
was centrifuged at 20,000 g for 20 min, which resulted in S2 and
the pellet 2 (P2; cell fragments and large vesicles). S2 was
ultracentrifuged at 110,000 g for 2 hr, which resulted in S3 and P3
(exosomes). A final centrifugation of S3 at 200,000 g for 2 hr
resulted in S4 and P4 (other microvesicles). We found that all
PLA2 activities were retained in the S1 through S4 fractions,
suggesting they were ‘‘free’’ and not associated with microvesicles
(detailed data not shown). This is similar to what we have recently
reported in human ovarian cancer ascites and novel secretion
mechanisms for iPLA2s and cPLA2s may be involved [16].
Clinical parameters and PLA2 activities in cancer plasma
samples
Interestingly, the natural, iPLA2, and sPLA2 activities in plasma
of CRC patients were increased in subjects with late stages (III and
IV) as compared to earlier stage (I and II) disease (P=0.0335,
0.0367, 0.0778, and 0.0345 for PLA2, iPLA2, cPLA2, and sPLA2,
respectively; Fig. 2), suggesting that these enzymatic activities may
be involved in CRC progression. We compared the PLA2 activities
in colon (n= 24) vs. rectal (n = 14) samples. Even though the
nature, as well the sub-group PLA2 activities in colon cancer
patients were higher than those from rectal cancer patients, the
differences were not statistically significant (P.0.05 in all cases;
Table 2). In addition, no difference was found in PLA2 activities
Table 3. Clinical characteristics and PLA2 activities in the LC, BC, and PC cases.
PLA2 iPLA2 cPLA2 sPLA2
No. Mean SD P value Mean SD P value Mean SD P value Mean SD P value
Lung
cancer
T stage 0.4760** 0.5001** 0.4960** 0.6129**
T1 19 1714.2 548.5 1626.6 514.2 2190.2 752.6 457.1 280.7
T2 21 1569.3 671.8 1490.6 640.6 1924.1 754.0 478.7 261.4
T3 9 1437.9 479.0 1347.4 460.7 1721.3 480.5 356.2 166.6
T4 35 1803.5 878.2 1691.8 823.9 2141.7 1105.9 471.5 228.4
N stage 0.9973** 0.9685** 0.9758** 0.8009**
N0 14 1626.7 566.2 1559.5 522.6 2061.3 584.4 386.3 143.2
N1 11 1574.8 508.1 1442.7 479.8 1960.3 671.2 404.1 200.4
N2 21 1613.9 643.7 1524.1 631.4 1961.6 883.6 434.1 222.9
N3 29 1604.2 671.7 1510.2 620.6 1944.3 888.0 454.8 270.0
Bladder
cancer
T stage 0.7482** 0.7320** 0.5790** 0.1793**
Tis 2 1736.6 429.9 1568.4 406.3 2046.9 355.0 395.2 119.1
T1 4 1326.0 525.4 1306.3 517.3 1717.4 525.6 299.2 222.9
T2 10 1833.5 832.3 1710.5 759.0 2207.7 1074.9 451.0 160.6
T3 7 1812.3 522.3 1833.4 506.3 2541.3 630.6 444.4 141.7
T4 8 1800.7 582.9 1630.9 544.2 2098.4 638.9 596.2 263.3
N stage 0.8224** 0.7579** 0.7786** 0.1010**
N0 10 1665.1 479.6 1535.2 446.2 2158.4 619.1 436.1 168.2
N1 5 1602.0 482.3 1549.8 507.6 1872.4 726.4 411.2 173.2
N2 8 1813.4 964.3 1806.0 881.1 2333.5 1107.6 400.4 180.1
N3 5 1937.5 428.0 1761.7 394.4 2135.4 234.1 671.9 287.7
Pancreatic
cancer
T stage 0.7748** 0.8479** 0.8488** 0.8453**
T1 1 1398.3 1294.2 1400.7 419.7
T2 12 1823.2 708.6 1730.9 647.8 2413.7 897.1 476.3 139.5
T3 8 2031.6 1477.7 1891.1 1421.5 2693.9 2009.0 556.0 286.2
T4 15 2279.0 1509.8 2077.8 1423.9 2741.7 1919.3 595.7 506.3
N stage 0.1928* 0.1448* 0.1243* 0.0671*
N0 9 2663.9 1855.8 2564.3 1749.6 3475.3 2290.2 699.2 377.1
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among different subgroups of CRC patients with previous
treatments (surgery, chemotherapy, radiotherapy, or untreated;
Table 2). In contrast, we found that PLA2 activities were not
correlated to either T or N stages of LC, BC, or PC (Table 3).
Impact of other factors on PLA2 activity
We have collected other factors, which might influence PLA2
activities, including smoking, alcohol consumption, and body-mass
index (BMI). For the CRC study, from the 80 subjects with
available smoking information (27 CRC and 53 healthy cases), the
majority (96%) of people did not smoke when the samples were
collected, with an average 50.5% people never smoked and 45.7%
of past smoker, and only 9.4% and 19.2% people had second hand
smoking exposure in each group. The smoking statuses were
similarly distributed in the two groups (P values .0.05; detailed
data in Table 4) and there were no statistical differences in PLA2
activities among different smoking statuses (Fig. 3A). In the second
set of study, the smoking statuses were significantly different
between healthy controls and each of the cancer groups with
higher percentages of people who were current, past, or second-
hand smokers in cancer groups (P values ,0.05, except in one
comparison, Table 5). Nevertheless, no statistical differences were
observed in the PLA2 activities among different smoking statuses,
Figure 3. The influence of smoking on plasma PLA2 activities. PLA2 activities in healthy and CRC samples with different smoking
statuses(a)and second hand smoking statuses(b). A. Comparison of PLA2 activities between different smoking statuses(a) and second hand smoking
statuses(b) in participants with LC, BC, and PC.
doi:10.1371/journal.pone.0057081.g003
Table 4. Smoking, alcohol consumption, and the BMI status
of participants from IUSM*.
Healthy CRC
No. % No. % P value
Smoking status
Current smoker 2 3.8 1 3.7 0.4609
Past smoker 18 34.0 13 48.2




No 48 90.6 21 80.8
Yes 5 9.4 5 19.2
Alcohol 0.2542
No 6 11.3 1 3.7
Yes 47 88.4 26 96.3
BMI (Mean 6 SD) 28.266.96 25.464.01 0.0272
*These data are available from a subset of the participants.
doi:10.1371/journal.pone.0057081.t004
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supporting the concept obtained from the first set of study that
plasma PLA2 activities are not affected by smoking (Fig. 3B).
Alcohol consumption in the control and CRC groups were not
significantly different (Table 4). The alcohol consumers in the
CRC groups tend to have higher levels of plasma PLA2 activities,
but the differences were not statistically significant (Fig. 4).
However, due to the low numbers in non-alcohol consumption
group (n= 7), we should interpret these data with caution. For
other cancers, similar results were obtained. Although there were
significant higher percentages of alcohol consumption subjects in
other cancer groups (Table 5), the PLA2 activities were not
significantly related to alcohol (Fig. 5).
The differences in PLA2 activities between sexes did not reach a
statistical significance in the control or any cancer groups in either
set of studies (Figs. 5A and 5B). Similarly, there was no difference
or correlation in PLA2 activities in subjects with BMI,25 vs. BMI
$25 groups in the CRC study (Figs. 6A and 6B), although the
mean BMI in the CRC and PC groups were significantly less than
those in control groups (Tables 4 and 5).
Age is one of the most clearly identified risk factors for
developing CRC and other cancers. The American Cancer
Society and the U.S. Preventive Services Task Force recommend
that people receive colonoscopy screenings every 10 years
beginning at age 50. We thus analyzed the age effects on PLA2
activities by dividing the subjects into two groups (age ,50 years,
n = 37 and $50 years, n = 78). Although there was a trend of
increased PLA2 activities in the $50 years-old group in the CRC
group, the differences were not statistically significant (Fig. 7A).
Similarly, no difference was detected between the two age groups
in the LC, BC, and PC set, although when all the subjects
(including healthy controls) were combined, there were significant
increases in PLA2 activates in the older subjects (Fig. 7B).
A direct comparison of the two sets of healthy controls showed
that although their sex, age, second-hand smoking, and alcohol
consumption were different, there were no differences in any PLA2
activity measured (Table 6). This further supports that plasma
PLA2 activities are not significantly affected by age, sex, alcohol
consumption, and/or smoking.
The classification performance of plasma PLA2 activities
Logistic regression was used to evaluate the classification
performance of PLA2 activities in cancers. All four PLA2
measurements were kept as predictors regardless of their
significance. The classification performances were summarized
by receiver operating characteristic (ROC) curves (Fig. 8).
Prediction formulas were generated using the parameter estimates.








where ‘‘PCRC’’ stands for the probability of having CRC. The
ROC curve shown in Fig. 8A has an area under the curve
(AUC) = 0.7502.
Since external validations would require an independent study,
we instead adopted internal methods to validate the classification
performances. Among different internal validation methods, it has
been shown that bootstrap outperforms jackknife, cross-validation
and data-splitting methods [19]. Therefore, bootstrap was adopted
for validation. In particular, the prediction formula was obtained
by fitting the same model for each bootstrapped sample. The
formula was applied to the original data to calculate the prediction
probabilities. The performance for this particular bootstrap
sample was summarized by AUC of the ROC curve. The overall
performance was evaluated by summarizing AUCs across 1,000
bootstrapped samples. In 95% of the 1000 bootstrapped samples,
AUCs are higher than 0.7143 for CRC vs. healthy. Therefore,
these results internally confirm the classification performances of
the models developed above.
The prediction formula and the ROC curve to separate all
cancer cases from healthy subjects in the second set of study are as
follows and shown in Fig. 8B, with an AUC=0.8337.
Table 5. Smoking and alcohol consumption status of participants from HOG study.
Healthy LC BC PC
No. % No. % P value No. % P value No. % P value
Smoking status ,0.0001 0.0017 0.016
Current smoker 4 5.1 29 30.5 4 12.9 7 18.4
Past smoker 25 31.6 58 61.1 19 61.3 16 42.1
Never smoked 50 63.3 8 8.4 8 25.8 15 39.5
Second hand smoke ,0.0001 0.0091 0.0741
No 32 40.5 10 10.5 4 13.8 9 23.7
Yes 47 59.5 85 89.5 25 86.2 29 76.3
Alcohol ,0.0001 0.0018 ,0.0001
No 23 29.6 67 70.5 19 61.3 31 81.6
Yes 56 70.4 28 29.5 12 38.7 7 18.4
BMI (Mean 6 SD) 28.365.55 26.566.76 0.0707 28.365.01 0.9625 25.966.17 0.0374
LC: Lung cancer; BC: Bladder cancer; PC: Pancreatic cancer.
All P values are comparisons between the cancer group and the healthy group.
doi:10.1371/journal.pone.0057081.t005
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This performance was validated in 1000 bootstrapped samples. In
95% of the 1000 bootstrapped samples, AUCs are higher than
0.8205 for LC, PC, BC combined vs. the second set of healthy
controls.
The prediction formulas and the ROC curves for the separate
LC, BC, and PC cases from healthy subjects in the second set of
study are listed below and Figs. 8C to 8E, with AUCs .0.811,
indicating good classification performances of the tests. For LC
versus healthy control, the AUC=0.8119 (Fig. 8C). In 95% of the
1000 bootstrapped sample, AUCs are higher than 0.7923.
Figure 4. The influence alcohol consumption on plasma PLA2 activities. Comparison of PLA2 activities between ‘‘non-alcohol’’ and ‘‘alcohol’’
groups with the healthy and CRC participants. A. Comparison of PLA2 activities between ‘‘non-alcohol’’ and ‘‘alcohol’’ groupsin the second set of
studies with healthy, LC, BC, and PC participants.
doi:10.1371/journal.pone.0057081.g004
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Figure 5. PLA2activities were not significantly different between male and female. PLA2 activity comparison in males and females in the
healthy and the CRC groups. A. PLA2 activity comparison in males and females in the healthy and other cancer groups. Data from all subjects in each
set of studies are also presented.
doi:10.1371/journal.pone.0057081.g005
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For BC versus healthy control, the AUC=0.8624 (Fig. 8D). In 95%







For PC versus healthy control, the AUC=0.8671. In 95% of the
1000 bootstrapped sample, AUCs are higher than 0.8426.
Figure 6. Comparison of PLA2 activities among different BMI groups. The subjected in healthy and CRC groups were divided into two
groups: BMI 18.5 to ,25 (For all subjects, n = 43) and BMI.25 (For all subjects, n = 80). A. The subjected in healthy and other cancer groups were
divided into two groups: BMI#25 (For all subjects, n = 80) and BMI.25 (For all subjects, n = 148).
doi:10.1371/journal.pone.0057081.g006
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Finally, since we have found that the PLA2 activities were
essentially no difference in the two sets of healthy controls, we
combined all healthy controls and all cancer cases in both sets of
studies and generated a combined formula, with an AUC=0.8011
(Fig. 8F). In 95% of the 1000 bootstrapped samples, AUCs are
higher than 0.7907.
Figure 7. PLA2activities were not significantly correlated to ages. The participants in healthy and CRC groups were divided into two groups:
age,50 (For all subjects, n = 42) and age $50 (For all subjects, n = 153). Student t-test was performed to analyze the differences between these two
groups. A. The participants in healthy and other cancer groups were divided into two groups: age,50 (For all subjects, n = 61) and age $50 (For all
subjects, n = 144). Student t-test was performed to analyze the differences between these two groups. ***P,0.001.
doi:10.1371/journal.pone.0057081.g007
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The sensitivities and specificities can be obtained from the ROC
curves shown in Fig. 8. For the CRC set of study, 60.5%
sensitivity and 77.9% of specificity were obtained (Table 7). For
the 2nd set of study and the data combined for both sets,
sensitivities .80% and the specificities .66% were obtained for
all cases (Table 7).
The potential contributions of other factors
Although most other demographic and/or environmental
factors tested were not significantly different in cancer and control
groups (Figs 3–7), we tested their potential contributions to the
performance when they are evaluated at individual levels. We kept
all four PLA2 measurements in the models, but let other predictors
subject to model selections at the significant level 0.05.
The prediction formula and the ROC curve to separate CRC
from healthy subjects in the first set of study are as follows and
shown in Fig. 9A, with an AUC=0.8162. In 95% of the 1000








The prediction formula and the ROC curve to separate all cancer
cases from healthy subjects in the second set of study are as follows









1:4151|(Currently not but used to smoke)
This performance was validated in 1000 bootstrapped samples. In
95% of the 1000 bootstrapped samples, AUCs are higher than
0.9625 for LC, PC, and BC combined vs. the second set of healthy
controls.
The prediction formulas and the ROC curves for the separate
LC, BC, and PC cases from healthy subjects in the second set of
study are listed below and Figs. 9C to 9E, with AUCs .0.968,
indicating high sensitivities and specifies of the tests. For LC versus
healthy control, the AUC=0.9742. In 95% of the 1000
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For BC versus healthy control, the AUC=0.9682. In 95% of the








For PC versus healthy control, the AUC=0.9907. In 95% of the








Finally, since we found that the PLA2 activities were essentially
no difference in the two sets of healthy controls, we combined all
healthy controls and all cancer cases in both sets of studies and
generated a combined formula, with an AUC=0.9140 (Fig. 9F).
In 95% of the 1000 bootstrapped samples, AUCs are higher than
0.9018.
Table 6. Comparison of two independent sets of healthy
controls.
1st set 2nd set
No. % No. % P value
Gender ,0.0001
Male 31 40.3 61 77.2
Female 46 59.7 18 22.8
Smoking status
Current smoker 2 3.8 4 5.1 0.889
Past smoker 19 35.8 25 31.6
Never smoked 32 60.4 50 63.3
Second hand smoke ,0.0001
No 48 90.6 32 40.5
Yes 5 9.4 47 59.5
Alcohol ,0.0001
No 6 11.3 23 29.6
Yes 47 88.4 56 70.4
Age (Mean 6 SD) 51.6613.5 42.7612.03 ,0.0001
PLA2 activities(Mean 6 SD)
PLA2 1135.96266.2 1156.36311.8 0.660
iPLA2 1082.06286.1 1105.46301.6 0.620
cPLA2 1246.16318.7 1287.86425.9 0.488
sPLA2 299.16164.7 293.96137.3 0.828
doi:10.1371/journal.pone.0057081.t006
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The sensitivities and specificities obtained with these ROC curves
with additional parameters are increased to .85% (except CRC
vs. healthy cases; Table 7).
Discussion
In this work, we have presented the first measurements of
plasma natural and subtype PLA2 activities and their performanc-
es as potential markers for four different cancers, CRC, LC, BC,
and PC. We have measured the PLA2 activities in more than 20
blood samples with or without adding 1.2 mM calcium (the
natural ionized calcium concentration in blood) to the final assay
mixtures and did not detect any significant differences. Hence, we
define the PLA2 activities obtained without any additives as the
‘‘natural’’ PLA2 activity. We have selected optimal conditions to
measure each sub-family of PLA2 activities. These modified
conditions do not co-exist in the blood. Therefore, it is not
surprising that the sum of the subfamily PLA2 activities is greater
than the ‘‘natural’’ PLA2 activity. However, it is important to note
that although modified conditions were used to obtain the
activities for subfamilies of PLA2s, the final results are from the
natural PLA2s present in the blood samples.
While the advantages of using convenient serologic markers are
obvious, no reliable blood markers for any of these cancers are
currently available. For CRC, developing/validating non-invasive
or minimally invasive detection methods is a major focus in the
field. Current methods include stool and blood tests, such as fecal
immunochemical tests (FITs) and guaiac-based fecal occult blood
testing (got). Although the specificity is high (.85%), these tests
have a low sensitivity (,23%) for colorectal adenomas and are
thus unlikely to be able to increase the early detection of CRC
[20,21]. Genetic stool tests detect mutations in stool that can be
found in CRC. A 21 genetic change test was found to be superior
to guaiac fecal occult blood test (gFOBT) for the detection of CRC
[20]. However, the sensitivity only reached 51.6% [20]. The
plasma PLA2 activities tests presented show promising initial
results in separating healthy controls from cancer patients with
sensitivities and specificities approximately 70%. The majority
solid cancers are highly heterogeneous, which is one of the major
reasons that any single or small set of markers can hardly detect
any specific cancer with very high sensitivity and specificity.
Testing the potential complementary values of other identified
markers in CRC and other cancers will be of high significance.
Interestingly, our results suggest that PLA2 activities are indepen-
dent of several common demographic and environmental factors.
In addition, we have compared 11 CRC blood samples collected
before and after surgeries and found that 7 of 11 had reduced
PLA2 activities (26.1610.9% reduction) and 4 of 11 had increased
PLA2 activities (37.7%611.7%). Among them, disease progression
data was available for only 6 subjects (3 from each group).
Interestingly, all 3 subjects from the reduced PLA2 activity group
had chemotherapy and complete response and all 3 subjects from
the increased PLA2 activity group had chemotherapy and disease
progression. These data were from a very limited number of
subjects, but suggest that the prognostic value of PLA2 activities
warrants further testing. We are fully aware that our studies are
limited to the cohort size and external validation in independent
and larger scale studies will be critical and hope that our report
will promote such studies.
Is a marker which may detect multiple types of cancers useful?
The answer is likely to be yes. Even after decades of efforts, the
success rate in finding highly specific markers for specific cancers
has been low. Prostate-specific antigen is an exception, but even
the value of this marker as a screening tool in prostate cancer has
been recently questioned [22]. Many tumor markers are known to
affect multiple cancers. Sensitive, minimally invasive, reproduc-
ible, and cost-effective blood biomarkers to detect multiple
malignancies are likely to be clinically significant and highly
valuable as routine first line detection. In addition, the PLA2
Figure 8. ROC curves of plasma PLA2 activities in different groups. CRC cases vs. healthy subjects. A. All cancers vs. healthy subjects in the
2nd set. B. Lung cancer vs. healthy subjects. C. Bladder cancer vs. healthy subjects. D. Pancreatic cancer vs. healthy subjects. E. All cancers vs. all
healthy subjects with combined two sets.
doi:10.1371/journal.pone.0057081.g008
Table 7. Sensitivities and specificities of PLA2 to distinguish different cancers from healthy cases.
Without other parameters With other parameters
Sensitivity Specificity Sensitivity Specificity
First set
CRC vs. Healthy 60.5% 77.9% 63.0% 75.5%
Second set
All cancer vs. healthy 81.1% 72.2% 87.2% 88.6%
LC vs. healthy 82.1% 67.1% 85.3% 91.1%
BC vs. healthy 80.6% 75.9% 87.1% 87.3%
PC vs. healthy 81.6% 77.2% 86.8% 96.2%
Combined two sets
Cancer vs. healthy 80.2% 66.7% 83.2% 81.1%
doi:10.1371/journal.pone.0057081.t007
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activity test is very easy to perform in any laboratory with a
fluorescent plate reader, and would be feasible to develop into an
automated test. Moreover, very small amounts samples (1–10 mL
of plasma) are needed to perform the test and the results can be
obtained in 1–2 hrs. Additional markers or more specific
modalities, such as colonoscopy or imaging are likely to be needed
to detect specific cancers.
Another major advantage of the test is that it is reproducible,
robotic, and stable. It is well-recognized that many blood markers
are sensitive to how blood samples are handled, processed, and
stored. It is almost impossible to unify these procedures in the USA
or anywhere in the world. Freeze-and-thaw is another well-known
factor affecting marker stability. These reasons account, at least in
part, for the fact that although thousands of markers have been
reported in the past decades, seldom have any of them been cross-
validated in different centers and moved to the clinic. We have
used two completely independent sets of human plasma samples,
which were processed somewhat differently (see Method for
details) and show that the PLA2 activities are highly compatible,
consistent in healthy controls, and are independent of several
demographic and environmental factors, making them more likely
to be useful markers. More independent studies with large samples
sizes need to be conducted to further evaluate the clinical
significance of our finding reported here.
A potential caveat of the clinical usage of PLA2 activity is that
these enzymes are known to be involved in inflammation and may
be elevated in patients with benign inflammatory diseases. This
needs to be experimentally tested in clinical samples. However,
there are mounting lines of evidence supporting the strong causal
connections between inflammation and cancers [23]. In particular,
chronic inflammation plays a pivotal role in the development of
CRC in patients with inflammatory bowel disease [24]. The
connection between inflammation and lung cancer has been
shown not coincidental but may indeed be causal [23]. In
addition, non-steroidal anti-inflammatory drugs has been associ-
ated with reduced risk to developing many types of cancers [25].
Thus, future studies on the significance of elevated PLA2 activity in
disease detection and progression prediction will be highly
interesting.
Our results also strongly imply that the PLA2 activities (which
may or may not correlate to their RNA or protein expression
levels) are potential targets for cancer treatment tested here. Most,
if not all previous PLA2 assays conducted in tissues or cell lines
mainly focus on their expression levels using PCR and IHC, which
are gene/protein specific, time-consuming, costly, and require
relatively large amount of samples to cover different isoforms of
PLA2s. Since there are more than 30 PLA2s, none of the previous
studies provide an overall picture of PLA2s in any cancer. More
importantly, their enzymatic activities, but not necessarily their
RNA and/or protein expression levels, are directly related to the
biological effects, since PLA2 activities are well-known to be
regulated post-transcriptionally [26,27]. This concept has been
supported in our recent pre-clinical (mouse models) and human
sample studies in ovarian cancer [16] and remain to be tested
further in other cancers.
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